This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.
Herpes zoster is associated with inflammation of the dorsal root ganglion and peripheral nerves, and this inflammation is considered to be an important causative factor for postherpetic neuralgia. Interventions aimed at reducing this inflammation should therefore be effective in decreasing the likelihood of developing postherpetic neuralgia. Epidural administration of corticosteroids and local anesthetics has been shown to be effective, but is associated with the risk of arachnoiditis. Subcutaneous injection in an outpatient setting may be effective in preventing postherpetic neuralgia and is also considerably safer. Calcitonin has previously been shown to be effective in the management of acute pain following amputation. Also it was used in a previous study to prevent complex regional pain syndrome in severe hemiplegic patients after stroke. Also, a previous case report revealed that IV calcitonin provided immediate and sustained improvement in post herpetic neuralgia for over two months, without adverse effects from the calcitonin therapy. However, no previous trials evaluated the effect of subcutaneous calcitonin as a preventive measure against the development of postherpetic neuralgia. We will conduct this study as we hypothesize that calcitonin therapy in patients with acute herpes zoster may be associated with better acute pain control and therefore may decrease the incidence of postherpetic neuralgia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
168
patients will receive subcutaneous salmon calcitonin 100 IU (ampoule = 1 ml) daily for three weeks
patients will receive subcutaneous saline (1 ml) daily for three weeks.
Tanta University Hospitals
Tanta, Gharbia Governorate, Egypt
RECRUITINGIncidence of postherpetic neuralgia at 3 months after rash onset.
A numeric rating scale (NRS) that ranged from 0 for "no pain" to 10 for "worst ever pain will be used to assess the degree of pain. Pain score more than (3) at 3 months after onset of acute herpes zoster rash will be considered positive for the occurrence of postherpetic neuralgia.
Time frame: 3 months after onset of acute herpes zoster rash.
Incidence of postherpetic neuralgia.
Pain score more than 3.
Time frame: 6 months after onset of acute herpes zoster rash.
Severity of acute herpes zoster pain.
A numeric rating scale (NRS) that ranged from 0 for "no pain" to 10 for "worst ever pain will be used to assess the degree of pain.
Time frame: Up to 1 month after onset of acute herpes zoster rash.
Number of medications used to treat pain.
Analgesics, anti-neuropathic pain medications and opioids will be recorded.
Time frame: up to 6 months after onset of acute herpes zoster rash.
Side effects
Vomiting
Time frame: Up to 1 month after onset of acute herpes zoster rash.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.